Zobrazeno 1 - 10
of 47
pro vyhledávání: '"Yumi Nonomura"'
Autor:
Taku Fujimura, Yota Sato, Kayo Tanita, Chunbing Lyu, Yumi Kambayashi, Ryo Amagai, Atsushi Otsuka, Yasuhiro Fujisawa, Koji Yoshino, Shigeto Matsushita, Hiroshi Uchi, Yuki Yamamoto, Hiroo Hata, Takeru Funakoshi, Yumi Nonomura, Ryota Tanaka, Hisako Okuhira, Naoko Wada, Akira Hashimoto, Setsuya Aiba
Publikováno v:
Frontiers in Medicine, Vol 6 (2019)
Anti-programmed cell death protein 1 (PD1) antibodies are in wide use for the treatment of various cancers. PD1 antibody-based immunotherapy, co-administration of nivolumab and ipilimumab, is one of the optimal immunotherapies, especially in advanced
Externí odkaz:
https://doaj.org/article/60775cb304df4e02a56684d41b7ab84f
Autor:
Taku Fujimura, Yota Sato, Kayo Tanita, Yumi Kambayashi, Atsushi Otsuka, Yasuhiro Fujisawa, Koji Yoshino, Shigeto Matsushita, Takeru Funakoshi, Hiroo Hata, Yuki Yamamoto, Hiroshi Uchi, Yumi Nonomura, Ryota Tanaka, Megumi Aoki, Keisuke Imafuku, Hisako Okuhira, Naoko Wada, Hiroyuki Irie, Takanori Hidaka, Akira Hashimoto, Setsuya Aiba
Publikováno v:
Frontiers in Oncology, Vol 8 (2018)
Antibodies against programmed cell death protein 1, such as nivolumab and pembrolizumab, are widely used for treating various cancers, including advanced melanoma. Nivolumab significantly prolongs survival in patients with metastatic melanoma, and se
Externí odkaz:
https://doaj.org/article/bd32b94688fe474fb8cbbc50d105f812
Autor:
Yumi Nonomura, Atsushi Otsuka, Yuichiro Endo, Akihiro Fujisawa, Miki Tanioka, Kenji Kabashima, Yoshiki Miyachi
Publikováno v:
Case Reports in Dermatology, Vol 4, Iss 2, Pp 177-180 (2012)
Extramammary Paget's disease is a rare cutaneous malignant neoplasm. Previous studies indicated the efficacy of docetaxel in advanced cases. The common side effects of docetaxel are usually tolerable and seldom life-threatening. We experienced a case
Externí odkaz:
https://doaj.org/article/17842560c38a47f380e215aa41678873
Autor:
Yoshihiro Ishida, Judith A. Seidel, Akihiko Kitoh, Mikio Hayashi, Takashi Nomura, Kenji Kabashima, Mutsuyoshi Matsushita, Lai San Wong, Chisa Nakashima, Yasuo Yamamoto, Tetsuya Honda, Saeko Nakajima, Atsushi Otsuka, Noriko Konishi, Wataru Amano, Yumi Nonomura, Teruki Dainichi
Publikováno v:
The Journal of allergy and clinical immunology. 148(3)
Background Sensory nerves regulate cutaneous local inflammation indirectly through induction of pruritus and directly by acting on local immune cells. The underlying mechanisms for how sensory nerves influence cutaneous acquired immune responses rema
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bab18b8b4a21b2896327be10ae9add63
https://pubmed.ncbi.nlm.nih.gov/34224784
https://pubmed.ncbi.nlm.nih.gov/34224784
Autor:
Shigemi Matsumoto, Motoo Nomura, Michio Yoshimura, Yo Kaku, Manabu Muto, Atsushi Otsuka, Yumi Nonomura
Publikováno v:
Cancer Chemotherapy and Pharmacology. 81:823-827
The objective of this study was to evaluate the efficacy and safety of concurrent immune checkpoint inhibitor therapy and radiotherapy (immunoradiotherapy) in patients with metastatic melanoma after progression on nivolumab. A retrospective review wa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6745c57cf9e2c7d88611852e0030401d
https://doi.org/10.1007/s00280-018-3557-0
https://doi.org/10.1007/s00280-018-3557-0
Autor:
Hiroo Hata, Yasuhiro Fujisawa, Hisako Okuhira, Atsushi Otsuka, Takeru Funakoshi, Keisuke Imafuku, Ryota Tanaka, Masahiko Gosho, Megumi Aoki, Kei Yamaguchi, Ikuko Hirai, Taku Fujimura, Yuki Yamamoto, Shigeto Matsushita, Sadanori Furudate, Koji Yoshino, Yumi Nonomura
Publikováno v:
Journal of Dermatological Science. 88:225-231
Background Although nivolumab significantly prolongs survival of metastatic melanoma, about 10% of patients experience severe, even fatal immune-related adverse events (irAEs). Biomarkers to predict irAEs are, therefore, of great interest. Objective
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3af38b8198e4543e29f73057b28f8036
https://doi.org/10.1016/j.jdermsci.2017.07.007
https://doi.org/10.1016/j.jdermsci.2017.07.007
Autor:
Hiroki Nagai, Shigemi Matsumoto, Tomohiro Kondo, Atsushi Otsuka, Motoo Nomura, Manabu Muto, Yumi Nonomura, Yo Kaku
Publikováno v:
Cancer Chemotherapy and Pharmacology. 80:999-1004
Nivolumab is a monoclonal antibody directed against programmed death-1 that has been shown to improve survival in patients with metastatic melanoma. However, the efficacy of nivolumab and other agents in melanoma remains limited. The objective of thi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0465ff0e929f5a6c4947d6c4fe6db442
https://doi.org/10.1007/s00280-017-3444-0
https://doi.org/10.1007/s00280-017-3444-0
Autor:
Sadanori Furudate, Taku Fujimura, K. Yamaguchi, Shigeto Matsushita, Keisuke Imafuku, Hisako Okuhira, Yuki Yamamoto, Ryota Tanaka, M. Aoki, Yumi Nonomura, Koji Yoshino, Hironobu Hata, Atsushi Otsuka, Yasuhiro Fujisawa, Takeru Funakoshi, Ikuko Hirai
Publikováno v:
British Journal of Dermatology. 179:213-215
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2fb7a620d18d84625c872002dddc5445
https://doi.org/10.1111/bjd.16427
https://doi.org/10.1111/bjd.16427
Autor:
Naomi Kitayama, Chisa Nakashima, Lai San Wong, Kenji Kabashima, Yumi Nonomura, Atsushi Otsuka, Yasuo Yamamoto, Kenji Usui, Tetsuya Honda
Publikováno v:
Journal of Dermatological Science. 89:207-209
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4de28f5909fcc07d3ab92b0757f5b238
https://doi.org/10.1016/j.jdermsci.2017.10.012
https://doi.org/10.1016/j.jdermsci.2017.10.012
Autor:
Hiroo Hata, Takeru Funakoshi, Yumi Kambayashi, Ryota Tanaka, Ryo Amagai, Atsushi Otsuka, Setsuya Aiba, Naoko Wada, Hisako Okuhira, Taku Fujimura, Yumi Nonomura, Yota Sato, Chunbing Lyu, Hiroshi Uchi, Yasuhiro Fujisawa, Yuki Yamamoto, Kayo Tanita, Koji Yoshino, Akira Hashimoto, Shigeto Matsushita
Publikováno v:
Frontiers in Medicine, Vol 6 (2019)
Frontiers in Medicine
Frontiers in Medicine
Anti-programmed cell death protein 1 (PD1) antibodies are in wide use for the treatment of various cancers. PD1 antibody-based immunotherapy, co-administration of nivolumab and ipilimumab, is one of the optimal immunotherapies, especially in advanced
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05232b0d4dc7dad8db7773daca884b1b
https://www.frontiersin.org/article/10.3389/fmed.2019.00086/full
https://www.frontiersin.org/article/10.3389/fmed.2019.00086/full